LYON, France , Oct. 13, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that data on clinical outcomes of its Ablatherm-HIFU FDA study (the "Enlight Trial") will be presented at the 4 th International Symposium of the Focused
LYON, France , Sept. 22, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that the growing interest in and acceptance of its Ablatherm®-HIFU technology was once again highlighted as a valuable treatment alternative for prostate cancer
Highlights Revenues increased 28% year-over-year to EUR 13.4 million for the first six months 104% growth in its HIFU business outside of USA for the first six months Solid financial profile with cash position of $17.5 million Strong backlog of orders in both HIFU and ESWL entering Third Quarter
LYON, France , Aug. 26, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced its participation in the Seventh International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which took place in Los Angeles , August 21-23,
LYON, France , Aug. 11, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2014 results announcement, which will take place on August 28, 2014 , before the opening of the market.
Responds to Gastroenterology and Urology Devices Panel Vote on Ablatherm-HIFU for Treatment of Prostate Cancer LYON, France , Aug. 5, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided comments on the recent Gastroenterology and Urology
